bromocriptine has been researched along with cabergoline in 199 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (2.51) | 18.7374 |
| 1990's | 36 (18.09) | 18.2507 |
| 2000's | 66 (33.17) | 29.6817 |
| 2010's | 71 (35.68) | 24.3611 |
| 2020's | 21 (10.55) | 2.80 |
| Authors | Studies |
|---|---|
| Audinot, V; Boutin, JA; Cussac, D; Maiofiss, L; Millan, MJ; Newman-Tancredi, A | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Demedts, M; Dom, R; Frans, E | 1 |
| Crosignani, P; D'Alberton, A; de Vincentiis, S; Ferrari, C; Mattei, AM; Paracchi, A | 1 |
| Barone, D; Benedetti, MS; Dostert, P; Efthymiopoulos, C; Peretti, G; Roncucci, R | 1 |
| Casazza, S; D'Alberton, A; de Vincentiis, S; Fadin, M; Giorda, G; Motta, T | 1 |
| Dominoni, P; Ferrari, L; Gianola, D; Gualteroni, L; Montini, M; Pagani, G; Pagani, MD; Sileo, F; Stroppa, S; Tengattini, F | 1 |
| Camanni, F; Ciccarelli, E; Giordano, G; Giusti, M; Miola, C; Potenzoni, F; Sghedoni, D | 1 |
| Baroldi, P; Cavioni, V; Crosignani, PG; Ferrari, C; Galparoli, C; Gerevini, G; Mattei, AM; Paracchi, A; Romano, C; Spellecchia, D | 1 |
| Cancio, E; Cocchi, D; Dall'Ara, A; Devesa, J; Di Salle, E; Lima, L; Müller, EE | 1 |
| Barbieri, C; Boghen, M; Caldara, R; Codecasa, F; Dubini, A; Ferrari, C; Mucci, M; Paracchi, A; Romano, C | 1 |
| Zaccheo, T | 1 |
| Arvigo, M; Barreca, A; Cariola, G; Foppiani, L; Giordano, G; Minuto, F; Ponzani, P | 1 |
| Arita, K; Eguchi, K; Ito, A; Kawamoto, K; Kurisu, K; Uozumi, T | 2 |
| Bryson, HM; Fitton, A; Rains, CP | 1 |
| Riva di Sanseverino, L; Sabatino, P; Tonani, R | 1 |
| Bosc, M; Leclere, J; Pascal-Vigneron, V; Weryha, G | 1 |
| Mark, MH; Sage, JI | 1 |
| Fraser, RB; Jones, TH | 1 |
| Ferrari, CI; Ismail, I; Piscitelli, G; Polli, A; Scanlon, MF; Webster, J | 1 |
| Serri, O | 1 |
| Colombo, N; D'Alberton, A; de Vincentiis, S; Marchini, M; Motta, T | 1 |
| Crosignani, PG; Ferrari, C; Piscitelli, G | 1 |
| Arai, N; Fukuyama, J; Isaji, M; Kuno, S; Miyata, H; Mizuta, E | 1 |
| Delgrange, E; Donckier, J; Maiter, D | 1 |
| Webster, J | 1 |
| Catz, T; Inzelberg, R; Kippervasser, S; Korczyn, AD; Nisipeanu, P; Orlov, E; Rabey, JM; Schechtman, E | 1 |
| Arai, N; Isaji, M; Itoh, F; Kojima, M; Miyagi, M; Taya, F; Ujiie, A | 1 |
| Cerbone, G; Cirillo, S; Colao, A; Di Sarno, A; Ferone, D; Lombardi, G; Marzullo, P; Merola, B; Sarnacchiaro, F | 1 |
| Korczyn, AD; Nisipeanu, P | 1 |
| Marsden, CD | 1 |
| Colao, A; Di Sarno, A; Di Somma, C; Facciolli, G; Klain, M; Landi, ML; Lombardi, G; Panza, N; Pivonello, R; Salvatore, M | 1 |
| Conner, P; Fried, G | 1 |
| Colao, A; De Rosa, M; Di Sarno, A; Ferone, D; Landi, ML; Lombardi, G; Merola, B; Paesano, L; Zarrilli, S | 1 |
| Crabbé, J; Delgrange, E; Donckier, J | 1 |
| Chervin, A; Fideleff, HL; Gurucharri, C; Holland, ME; Sinai, I | 1 |
| Inada, Y; Kojima, M; Komatsu, H; Miyata, H; Moro, M; Torii, R | 1 |
| Abs, R; Beckers, A; Coremans, P; Lamberigts, G; Mahler, C; Maiter, D; Mockel, J; Petrossians, P; Raftopoulos, C; Stevenaert, A; van den Bruel, A; Vandeweghe, M; Velkeniers, B; Verhelst, J; Verlooy, J | 1 |
| Montastruc, JL; Rascol, O; Senard, JM | 1 |
| Atkin, SL; Foy, PM; Hadden, DR; Leong, KS; MacFarlane, IA; Swift, AC | 1 |
| Colao, A; Di Sarno, A; Di Somma, C; Klain, M; Loche, S; Lombardi, G; Pietrosante, M; Pivonello, R; Salvatore, M | 1 |
| Brannan, T; Prikhojan, A; Yahr, MD | 1 |
| Tollin, SR | 1 |
| De Santis, L; Doldi, N; Ferrari, A; Papaleo, E | 1 |
| Agostini, S; Billeci, D; Conte, N; De Menis, E; Marton, E; Tramontin, P; Visentin, A | 1 |
| Clarke, CE; Deane, KD | 1 |
| de la Sota, RL; Gobello, C; Goya, RG | 1 |
| Atkinson, AB; Bell, PM; Courtney, CH; Ellis, PK; Hadden, DR; Leslie, H; McCance, DR; Sheridan, B | 1 |
| Arikan, E; Hatemi, H; Sabuncu, T; Tasan, E | 1 |
| Cappabianca, P; Colao, A; Di Salle, F; Di Sarno, A; Di Somma, C; Faggiano, A; Landi, ML; Lombardi, G; Pivonello, R; Rossi, FW | 1 |
| Colao, A; di Sarno, A; di Somma, C; Lombardi, G; Pivonello, R | 1 |
| Liu, C; Tyrrell, JB | 1 |
| Freed, DJ; Gillam, MP; Middler, S; Molitch, ME | 1 |
| Gekht, AB | 1 |
| Mah, PM; Webster, J | 1 |
| Cavallero, D; Fazzuoli, L; Giusti, M; Valenti, S | 1 |
| Goadsby, PJ; Levy, MJ; Matharu, MS | 1 |
| Fujinami, A; Kuno, S; Matsui, H; Mizuta, I; Ohta, K; Ohta, M | 1 |
| Bankowski, BJ; Zacur, HA | 1 |
| Broglia, G; Castex, G; Corrada, Y; Gobello, C | 1 |
| Ball, SG; Hall, K; James, RA; Kendall-Taylor, P; Pearce, SH; Quinton, R; Sibal, L; Ugwu, P | 1 |
| Molitch, ME | 4 |
| Braucks, GR; Gadelha, MR; Naliato, EC; Tabet, AL; Violante, AH | 1 |
| Chang, JY; Kattah, JC; Orth, EH; Talkad, AV; Xu, MY | 1 |
| Hotta, M; Kamo, T; Kawakami, M; Nemoto, S; Oshima, J; Shimojo, S; Shiraishi, M; Sugihara, H; Takahashi, Y; Yasaki, S | 1 |
| Couldwell, WT; Liu, JK | 1 |
| Grosset, D; Grosset, K; Macphee, G; Needleman, F | 1 |
| Baran, AS; Rack, MJ; Richert, AC; Roffwarg, HP | 1 |
| Basu, S; Chaudhuri, KR; Dhawan, V; Jackson, G; Odin, P | 1 |
| Trifonov, I | 1 |
| Casulari, LA; Mello, PA; Naves, LA; Papadia, C; Pereira Neto, A | 1 |
| Brooks, PL; Vella, ET; Wynne-Edwards, KE | 1 |
| Newell-Price, J; Ross, R; Selvarajah, D; Webster, J | 1 |
| Goetz, CG; Poewe, W; Rascol, O; Sampaio, C | 1 |
| Abs, R; Verhelst, J | 1 |
| Goadsby, PJ; Levy, MJ; Matharu, MS; Meeran, K; Powell, M | 1 |
| Howell, DL; Hudgins, RJ; Mazewski, CM; Meacham, LR; Wasilewski, K | 1 |
| Biswas, M; Davies, JS; Evans, LM; Jadon, D; McEwan, P; Rees, DA; Scanlon, MF; Smith, J | 1 |
| Crosignani, PG | 1 |
| Góth, MI; Iván, G; Nagy, GM; Oláh, M; Szigeti-Csúcs, N | 1 |
| Bronstein, MD | 2 |
| Boulos, PT; Hamilton, DK; Laws, ER; Vance, ML | 1 |
| Barlier, A; Jaquet, P | 1 |
| Colao, A; De Leo, M; Di Sarno, A; Guerra, E; Lombardi, G; Mentone, A | 1 |
| Burger, E; Härtter, S; Kvernmo, T | 1 |
| Mascarell, S; Sarne, DH | 1 |
| Tokhunts, KA | 1 |
| Colao, A; Di Somma, C; Lombardi, G; Pivonello, R; Savastano, S; Tauchmanovà, L | 1 |
| Chuang, E; Molitch, ME | 1 |
| Greenman, Y | 1 |
| Horikawa, F; Kawabata, Y; Miki, N; Miyake, H; Ono, M; Ueno, Y | 1 |
| Caldas, D; Cesar de Oliveira Naliato, E; Colao, A; Dutra Violante, AH; Fontes, R; Gomes de Souza, R; Guerra, E; Lamounier Filho, A; Rezende Loureiro, C; Schrank, Y; Sebastian, A; Vaisman, M | 1 |
| Daida, H; Hatano, T; Hattori, N; Iwama, Y; Komine-Kobayashi, M; Mizuno, Y; Mochizuki, H; Nakayama, T; Sakai, M; Urabe, T; Yamashiro, K | 1 |
| Acharya, SV; Bandgar, TR; Gopal, RA; Joshi, SR; Menon, PS; Shah, NS | 1 |
| Doi, K; Isono, T; Kawamura, T; Kitagawa, N; Kuno, S; Masaki, M; Mizuta, E; Oeda, T; Sawada, H; Taniguchi, S; Yaku, H; Yamamoto, K; Yutani, C | 1 |
| Andersohn, F; Garbe, E | 1 |
| Martin, NM; Meeran, K; Tan, T | 1 |
| Fujioka, S; Iwamoto, K; Kawamura, M; Nakajima, M; Ohno, H | 1 |
| Pullan, PT | 1 |
| Bahuleyan, B; Easwer, HV; Krishna, K; Menon, G; Nair, S; Rao, BR | 1 |
| Ajitkumar, G; Ghosh, KN; Mercy, KA; Praseeda, R; Sreekumaran, T | 1 |
| Albuquerque, JL; Azevedo, MF; Boguszewski, CL; Bronstein, MD; Casulari, LA; de Oliveira, AR; Dos Santos Faria, M; Gadelha, MR; Montenegro, RM; Musolino, NR; Naves, LA; Pinho Barbosa, FR; Ramos, AJ; Serfaty, FM; Vilar, L | 1 |
| Atis, A; Aydin, Y; Goker, N; Kaleli, S; Uludağ, S | 1 |
| Amano, K; Hori, T; Izumi, S; Kawamata, T; Makino, R; Miki, N; Okada, Y; Ono, M; Seki, T; Takano, K | 1 |
| Klibanski, A | 1 |
| Bahceci, M; Sismanoglu, A; Ulug, U | 1 |
| Babakhani, L; Fereshtehnejad, SM; Mojthahedi, K; Motazedian, S | 1 |
| Barbosa, FR; Domingues, RC; dos Santos Silva, CM; Fontes, R; Gadelha, MR; Lima, GA; Warszawski, L | 1 |
| Burger, P; Menucci, M; Quiñones-Hinojosa, A; Salvatori, R | 1 |
| Freudenmann, RW; Gahr, M; Kölle, MA | 1 |
| Boguszewski, CL; dos Santos Nunes, V; El Dib, R; Nogueira, CR | 1 |
| Adamidou, F; Anagnostis, P; Efstathiadou, Z; Karathanassi, E; Kita, M; Polyzos, SA | 1 |
| Azevedo, M; Boguszewski, CL; de Souza, AM; dos Santos, CM; Marini, LC; Sakamoto, KS | 1 |
| Bernard, N; Descotes, J; Gillet, A; Gouraud, A; Mirkou, A; Suchovsky, D; Vial, T | 1 |
| Abad, A; Aller, J; Batista, E; Doltra, A; García-Pavía, P; Halperin, I; Lucas, T; Mirelis, JG; Mora, M; Puig-Domingo, M; Santos, AE; Sitges, M; Varela, C | 1 |
| Elenkova, A; Kalinov, K; Shabani, R; Zacharieva, S | 1 |
| Berardini, A; Biagini, E; Graziosi, M; Pazzi, C; Rapezzi, C; Rosmini, S | 1 |
| Bilge, A; Kurtulmus, N; Yarman, S | 1 |
| Deukmedjian, AR; Hann, S; Morrison, AD; Shah, V; Vale, FL | 1 |
| Bancroft, T; Burton, T; Le Nestour, E; Neary, M | 1 |
| Ahtiainen, P; Calandra, RS; Di Giorgio, NP; Gonzalez, B; Huhtaniemi, IT; Poutanen, M; Ratner, LD; Rulli, SB | 1 |
| Alkabbani, A; Doshi, K; Hamrahian, A; Hatipoglu, B; Kennedy, L; Makin, V; Mon, SY; Olansky, L; Thorton, JN; Weil, R | 1 |
| Abaci, A; Altincik, A; Bober, E; Buyukgebiz, A; Can, S; Catli, G; Demir, K | 1 |
| Hashida, H; Hattori, N; Iijima, M; Kano, O; Kubo, S; Matsumura, M; Murakami, H; Nanri, K; Okuma, Y; Suzuki, M; Suzuki, Y; Tomimitsu, H; Utsumi, H | 1 |
| Agúndez, JA; Alonso-Navarro, H; García-Martín, E; Jiménez-Jiménez, FJ | 1 |
| Góth, M | 1 |
| Cuevas, JL; Fernández, V; González, O; Rojas, D; Torche, E; Wohllk, N | 1 |
| Hisanaga, R; Nakamura, M; Nomoto, S; Sato, T | 1 |
| Descamps, P; Jeanneteau, P; Mercier, MB; Parot-Schinkel, E; Sentilhes, L | 1 |
| Barkan, A; Benbassat, C; Bronstein, MD; Shapiro, J; Shimon, I; Tsvetov, G | 1 |
| Figueroa-Núñez, C; González, E; Gutierrez, M; Hernán Martínez, J; Mangual-García, M; Mansilla-Letelier, P; Miranda, Mde L; Palermo-Garofalo, C; Sánchez, A; Santiago, M; Torres, O; Trinidad, R | 1 |
| Bonadei, I; Curnis, A; D'Aloia, A; Metra, M; Piovanelli, B; Rovetta, R; Vizzardi, E | 1 |
| Beketić-Orešković, L; Ježek, D; Kasum, M; Orešković, S; Pekez, M; Stanić, P; Vrčić, H | 1 |
| Krysiak, R; Okopien, B | 1 |
| Aydogan, U; Cengiz, M; Ercan, CM; Ergun, A; Ide, T; Kayaalp, O; Keskin, U; Yumusak, N | 1 |
| Akbaba, G; Arduc, A; Aydin, Y; Berker, D; Gokay, F; Guler, S; Isik, S; Kucukler, FK; Ozuguz, U; Tutuncu, Y | 1 |
| Elenkova, A; Gerenova, J; Hristozov, K; Kalinov, K; Kamenov, Z; Kirilov, G; Marinov, M; Natchev, E; Orbetzova, M; Tcharaktchiev, D; Tsinlikov, I; Vandeva, S; Yaneva, M; Zacharieva, S | 1 |
| Cámara Gómez, R; Del Olmo García, M; Merino Torres, JF; Querol Ripoll, R; Simal Julián, JA | 1 |
| Couldwell, WT; Eloy, JA; Liu, JK; Wong, A | 1 |
| Krysiak, R; Okopien, B; Okrzesik, J | 1 |
| Couldwell, WT; Eloy, JA; Hajart, AF; Jethwa, PR; Liu, JK; Patel, TD | 1 |
| Lamos, EM; Levitt, DL; Munir, KM | 1 |
| Dogansen, SC; Selcukbiricik, OS; Tanrikulu, S; Yarman, S | 1 |
| Alfieri, A; Ballarino, MC; Boero, L; Chervin, A; Danilowicz, K; Diez, S; Fainstein Day, P; García-Basavilbaso, N; Glerean, M; Guitelman, M; Katz, D; Loto, MG; Mallea-Gil, MS; Manavela, M; Martinez, M; Miragaya, K; Moncet, D; Rogozinski, AS; Servidio, M; Stalldecker, G; Vitale, M | 1 |
| Bronstein, MD; Espinosa, E; Glezer, A; Greenman, Y; Mendoza, V; Mercado, M; Popovic, V; Shimon, I; Sosa, E; Tirosh, A | 1 |
| Cooper, O; Gertych, A; Greenman, Y; Jonas-Kimchi, T; Melmed, S; Ram, Z; Robenshtok, E; Sagiv, N; Shimon, I; Stern, N; Yaish, I; Yuan, X | 1 |
| Blankley, G; Galbally, M; Power, J; Snellen, M | 1 |
| Chapman, IM; De Sousa, SM; Falhammar, H; Torpy, DJ | 1 |
| Atkinson, JL; Donegan, D; Erickson, B; Erickson, D; Jentoft, M; Meyer, F; Natt, N; Nippoldt, TB | 1 |
| Andereggen, L; Andres, RH; Beck, J; Christ, E; El-Koussy, M; Frey, J; Seiler, RW | 1 |
| Hart, RJ; Mourad, S; Tang, H; Zhai, SD | 1 |
| Dhanjal, MK; Knight, M; Lambert, K; McCance, DR; Rees, K; Seed, PT; Williamson, C | 1 |
| Beckers, A; Bonneville, JF; Brue, T; Castinetti, F; Cuny, T; Dufour, H; Eroukhmanoff, J; Potorac, I; Tejedor, I; Touraine, P; Weryha, G | 1 |
| Carvalho, D; Souteiro, P; Teixeira, M | 1 |
| Araujo, B; Belo, S; Carvalho, D | 1 |
| Ji, MJ; Kim, JH; Kim, SY; Kim, YH; Lee, JH; Paek, SH; Shin, CS | 1 |
| Cha, HJ; Kim, JH; Kim, SW; Kim, YH; Lee, JH; Lee, SY; Paek, SH; Shin, CS | 1 |
| Čehić, E; Franulić, D; Grgić, F; Kasum, M; Lila, A; Orešković, S; Vujić, G | 1 |
| Bilbao, I; Egaña, N; García, C; Olaizola, I | 1 |
| Ahangari, G; Bakhtou, H; Deezagi, A; Olfatbakhsh, A | 1 |
| Huang, HY; Lin, SJ; Wu, ZB; Zhao, WG | 1 |
| Arlt, W; Ayuk, J; Fountas, A; Gittoes, N; Karavitaki, N; Santharam, S; Tampourlou, M; Toogood, A | 1 |
| Huang, HY; Hui, GZ; Tang, H; Wu, ZB; Zhai, W | 1 |
| Maiter, D | 1 |
| Cong, Z; Luo, X; Ma, C; Sun, R; Tang, C; Wen, G; Yang, J; Zhong, C; Zhu, J | 1 |
| Akinduro, OO; Bernet, V; Chaichana, KL; De Biase, G; Donaldson, A; Izzo, A; Lu, VM; Meyer, FB; Olomu, O; Quinones-Hinojosa, A; Van Gompel, JJ; Vilanilam, G | 1 |
| Colwell, HH; Fleseriu, M; Fogelfeld, L; Gordon, MB; Haviv, A; Ludlam, WH; Mathias, SD; Sisco, J | 1 |
| Farrant, MT; Gunn, AJ; Milsom, SR; O'Sullivan, SM; Ogilvie, CM | 1 |
| Okayama, A; Sato, T; Shimatsu, A; Yamaguchi, H | 1 |
| Kawakami, K; Matsubayashi, K | 1 |
| Hart, RJ; Mourad, SM; Tang, H; Wang, A; Zhai, SD | 1 |
| Biermasz, NR; Chanson, P; Jorgensen, JOL; Kuhn, E; Weinreich, AA | 1 |
| Abd El Latif, HA; El Yamani, M; Fouad Shalaby, MA; Galal, MA; Kamal, S; Masaood, R; Sindi, I | 1 |
| Chen, S; Dong, J; Gu, J; Jiang, X; Li, D; Wen, X; Zou, Y | 1 |
| Cai, X; Cong, Z; Ma, C; Tang, C; Yang, J; Yuan, F; Zhu, J | 1 |
| Auriemma, RS; Colao, A; Negri, M; Patalano, R; Pirchio, R; Pivonello, C; Pivonello, R | 1 |
| Canturk, S; Dogansen, S; Hacisahinogullari, H; Yarman, S | 1 |
| Kasica, N; Mackiewicz, J; Osęka, M; Saładziak, K; Święch, A | 1 |
| Akhtar, MF; Akter, R; Al-Harrasi, A; Berrada, M; Bhatia, S; Damiri, F; Ferdous Mitu, J; Kabir, MT; Rahman, MH; Rahman, MS; Saleem, A | 1 |
| Inder, WJ; Jang, C | 1 |
| Hamidianjahromi, A; Tritos, NA | 1 |
| Auriemma, RS; Colao, A; Graziadio, C; Pirchio, R; Pivonello, R | 1 |
| Bauersachs, J; Berliner, D; Erschow, S; Haebel, L; Hilfiker-Kleiner, D; Koenig, T; Mueller, JH; Pfeffer, TJ; Ricke-Hoch, M; Scherr, M; Talbot, SR; Yalman, KC; Zwadlo, C | 1 |
| Arastu, MI; Curiale, AM; Lipton, BA; Longo, S; Nanda, S; Tessier, S | 1 |
| Huang, Q; Li, M; Tan, J; Zeng, Y; Zhou, W; Zou, Y | 1 |
| Cescato, VAS; Cunha-Neto, MBC; Glezer, A; Musolino, NRC; Pinheiro, FMM; Silva, GO; Stumpf, MAM | 1 |
| Miller, KK; Tritos, NA | 1 |
| Attanasio, R; Basile, M; Bozzao, A; Cappabianca, P; Caputo, M; Cozzi, R; Cruciani, F; De Menis, E; Doglietto, F; Esposito, F; Ferrante, E; Ferraù, F; Grimaldi, F; Iatì, G; Lania, AG; Laureti, S; Lello, S; Locatelli, D; Maffei, P; Mazzatenta, D; Minniti, G; Mitrova, Z; Paoletta, A; Papini, E; Peri, A; Persichetti, A; Poggi, M; Rudà, R; Ruini, C; Samperi, I; Saulle, R; Scoppola, A; Settanni, F; Silvani, A; Simona Auriemma, R; Tortora, F; Vecchi, S; Veronese, N | 1 |
52 review(s) available for bromocriptine and cabergoline
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
New drugs for hyperprolactinaemia.
Topics: Aminoquinolines; Bromocriptine; Cabergoline; Clinical Trials as Topic; Ergolines; Hormone Antagonists; Humans; Hyperprolactinemia | 1995 |
Cabergoline. A review of its pharmacological properties and therapeutic potential in the treatment of hyperprolactinaemia and inhibition of lactation.
Topics: Administration, Oral; Antineoplastic Agents; Biological Availability; Bromocriptine; Cabergoline; Dopamine Agonists; Dose-Response Relationship, Drug; Ergolines; Female; Humans; Hyperprolactinemia; Lactation; Prolactin; Tissue Distribution | 1995 |
Cabergoline: a new drug for the treatment of hyperprolactinaemia.
Topics: Bromocriptine; Cabergoline; Clinical Trials as Topic; Dopamine Agonists; Dose-Response Relationship, Drug; Double-Blind Method; Ergolines; Female; Humans; Hyperprolactinemia; Lactation; Postpartum Period; Randomized Controlled Trials as Topic | 1995 |
A comparative review of the tolerability profiles of dopamine agonists in the treatment of hyperprolactinaemia and inhibition of lactation.
Topics: Aminoquinolines; Animals; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Hyperprolactinemia; Lactation; Male; Pregnancy | 1996 |
Newer therapies for Parkinson's disease.
Topics: Antiparkinson Agents; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Humans; Indoles; Parkinson Disease | 1996 |
Clinical experience with cabergoline in patients with advanced Parkinson's disease treated with levodopa.
Topics: Antiparkinson Agents; Bromocriptine; Cabergoline; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Ergolines; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Randomized Controlled Trials as Topic | 1998 |
Hyperprolactinemia; etiology, diagnosis and treatment alternatives.
Topics: Aminoquinolines; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Hyperprolactinemia; Pergolide; Prolactin; Receptors, Prolactin | 1998 |
Treatment of Parkinson's disease should begin with a dopamine agonist.
Topics: Benzothiazoles; Bromocriptine; Cabergoline; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Therapy, Combination; Ergolines; Humans; Indoles; Levodopa; Lisuride; Parkinson Disease; Pergolide; Pramipexole; Receptors, Dopamine D2; Thiazoles | 1999 |
CSF rhinorrhoea following treatment with dopamine agonists for massive invasive prolactinomas.
Topics: Adult; Bromocriptine; Cabergoline; Cerebrospinal Fluid Rhinorrhea; Dopamine Agonists; Ergolines; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Pituitary Neoplasms; Prolactinoma; Tomography, X-Ray Computed | 2000 |
Cabergoline versus bromocriptine for levodopa-induced complications in Parkinson's disease.
Topics: Antiparkinson Agents; Bromocriptine; Cabergoline; Dopamine Agonists; Dyskinesia, Drug-Induced; Ergolines; Humans; Levodopa; Parkinson Disease; Randomized Controlled Trials as Topic | 2001 |
Dopamine receptor agonists for treating prolactinomas.
Topics: Aminoquinolines; Animals; Bromocriptine; Cabergoline; Dopamine Agonists; Drug Resistance, Neoplasm; Ergolines; Ergot Alkaloids; Female; Humans; Pergolide; Pituitary Neoplasms; Pregnancy; Prolactin; Prolactinoma | 2002 |
DA agonists -- ergot derivatives: bromocriptine: management of Parkinson's disease.
Topics: Benzophenones; Bromocriptine; Cabergoline; Dopamine Agonists; Drug Therapy, Combination; Enzyme Inhibitors; Ergolines; Ergot Alkaloids; Humans; Levodopa; Lisuride; Nitrophenols; Parkinson Disease; Pergolide; Randomized Controlled Trials as Topic; Tolcapone | 2002 |
[Use of dopamine agonists in the treatment of Parkinson's disease].
Topics: Antiparkinson Agents; Benzothiazoles; Bromocriptine; Cabergoline; Controlled Clinical Trials as Topic; Dopamine Agonists; Ergolines; Humans; Indoles; Lisuride; Parkinson Disease; Pergolide; Piribedil; Placebos; Pramipexole; Serotonin Receptor Agonists; Thiazoles; Time Factors | 2002 |
Hyperprolactinemia: etiology, diagnosis, and management.
Topics: Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Humans; Hyperprolactinemia; Neurosurgical Procedures; Prevalence | 2002 |
Dopamine agonist therapy for hyperprolactinemia.
Topics: Aminoquinolines; Benzothiazoles; Bromocriptine; Cabergoline; Clinical Trials as Topic; Dopamine Agonists; Ergolines; Ergoloid Mesylates; Female; Humans; Hyperprolactinemia; Indoles; Pergolide; Pramipexole; Thiazoles | 2003 |
Dopamine resistance of prolactinomas.
Topics: Bromocriptine; Cabergoline; Dopamine Agonists; Drug Resistance; Ergolines; Humans; Pituitary Neoplasms; Prolactinoma | 2003 |
Contemporary management of prolactinomas.
Topics: Bromocriptine; Cabergoline; Contraindications; Diagnosis, Differential; Ergolines; Female; Humans; Hypophysectomy; Magnetic Resonance Imaging; Male; Pituitary Diseases; Pituitary Neoplasms; Pregnancy; Pregnancy Complications, Neoplastic; Prolactin; Prolactinoma; Radiosurgery; Remission Induction | 2004 |
[Prolactinoma and pregnancy].
Topics: Aminoquinolines; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Pituitary Neoplasms; Pregnancy; Pregnancy Complications, Neoplastic; Prolactinoma | 2004 |
Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004.
Topics: Amantadine; Antiparkinson Agents; Apomorphine; Benzophenones; Benzothiazoles; Bromocriptine; Cabergoline; Catechol O-Methyltransferase Inhibitors; Deep Brain Stimulation; Dihydroergocryptine; Ergolines; Fetal Tissue Transplantation; Globus Pallidus; Humans; Indans; Indoles; Levodopa; Lisuride; Mesencephalon; Monoamine Oxidase Inhibitors; Neurosurgical Procedures; Nitrophenols; Parkinson Disease; Pergolide; Piribedil; Pramipexole; Selegiline; Thiazoles; Tolcapone | 2005 |
Hyperprolactinemia: pathophysiology and management.
Topics: Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Estrogens; Female; Humans; Hyperprolactinemia; Male; Pergolide; Pituitary Neoplasms; Pregnancy; Prolactin; Prolactinoma; Radiotherapy; Surgical Procedures, Operative | 2003 |
Current treatment issues in female hyperprolactinaemia.
Topics: Aminoquinolines; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Hyperprolactinemia; Male; Pituitary Neoplasms; Pregnancy; Prolactinoma | 2006 |
Treatment of pituitary tumors: dopamine agonists.
Topics: Adenoma; Bromocriptine; Cabergoline; Dopamine; Dopamine Agonists; Ergolines; Humans; Pituitary Neoplasms; Receptors, Dopamine | 2005 |
Prolactinomas and pregnancy.
Topics: Aminoquinolines; Bromocriptine; Cabergoline; Child; Dopamine Agonists; Ergolines; Female; Humans; Magnetic Resonance Imaging; Pituitary Neoplasms; Pregnancy; Pregnancy Complications, Neoplastic; Prolactinoma | 2005 |
Pharmacologic resistance in prolactinoma patients.
Topics: Bromocriptine; Cabergoline; Cell Proliferation; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Resistance; Ergolines; Estrogens; Female; Humans; Male; Pergolide; Pituitary Neoplasms; Prolactin; Prolactinoma; Receptors, Dopamine D2 | 2005 |
Quinagolide--a valuable treatment option for hyperprolactinaemia.
Topics: Administration, Oral; Aminoquinolines; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Hyperprolactinemia; Male; Patient Compliance | 2006 |
Drug insight: Cabergoline and bromocriptine in the treatment of hyperprolactinemia in men and women.
Topics: Adenoma; Antineoplastic Agents; Bromocriptine; Cabergoline; Ergolines; Female; Humans; Hyperprolactinemia; Male; Prolactin; Prolactinoma; Sex Characteristics | 2006 |
A review of the receptor-binding and pharmacokinetic properties of dopamine agonists.
Topics: Animals; Bromocriptine; Cabergoline; Dopamine Agonists; Drug Interactions; Dyskinesia, Drug-Induced; Ergolines; Heart Valve Diseases; Humans; Indoles; Pergolide; Pulmonary Fibrosis; Receptors, Dopamine | 2006 |
Clinical practice. Prolactinomas.
Topics: Adult; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Magnetic Resonance Imaging; Male; Pituitary Neoplasms; Practice Guidelines as Topic; Pregnancy; Pregnancy Complications, Neoplastic; Prolactin; Prolactinoma; Visual Fields | 2010 |
Cabergoline versus bromocriptine in the treatment of hyperprolactinemia: a systematic review of randomized controlled trials and meta-analysis.
Topics: Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Humans; Hyperprolactinemia; Randomized Controlled Trials as Topic | 2011 |
Prolactinoma in pregnancy.
Topics: Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Female; Fetus; Humans; Hyperprolactinemia; Infertility, Female; Pregnancy; Pregnancy Complications, Neoplastic; Prolactinoma | 2011 |
Anti-Parkinson's disease drugs and pharmacogenetic considerations.
Topics: Aryl Hydrocarbon Hydroxylases; Benzothiazoles; Benztropine; Bromocriptine; Cabergoline; Catechols; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Ergolines; Genetic Markers; Humans; Indans; Indoles; Levodopa; Lisuride; Nitriles; Parkinson Disease; Pergolide; Pharmacogenetics; Pramipexole; Receptors, Dopamine D2; Receptors, Dopamine D3; Reproducibility of Results; Selegiline | 2013 |
[Drug therapy for acromegaly].
Topics: Acromegaly; Aminoquinolines; Antineoplastic Agents, Hormonal; Bromocriptine; Cabergoline; Dopamine Agonists; Drug Administration Schedule; Drug Therapy, Combination; Ergolines; Human Growth Hormone; Humans; Insulin-Like Growth Factor I; Interdisciplinary Communication; Membrane Proteins; Octreotide; Patient Care Team; Peptides, Cyclic; Pituitary Neoplasms; Somatostatin | 2013 |
Dopamine agonists in prevention of ovarian hyperstimulation syndrome.
Topics: Aminoquinolines; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Ovarian Hyperstimulation Syndrome; Ovulation Induction | 2014 |
Update on prolactinomas. Part 2: Treatment and management strategies.
Topics: Bromocriptine; Cabergoline; Disease Management; Dopamine Agonists; Drug Administration Schedule; Drug Resistance, Neoplasm; Ergolines; Female; Humans; Hyperprolactinemia; Magnetic Resonance Imaging; Neoplasm Recurrence, Local; Neuroendoscopy; Pituitary Neoplasms; Pregnancy; Pregnancy Complications, Neoplastic; Prolactin; Prolactinoma; Radiosurgery; Sphenoid Sinus | 2015 |
A review of dopamine agonist therapy in type 2 diabetes and effects on cardio-metabolic parameters.
Topics: Animals; Biomarkers; Blood Glucose; Bromocriptine; Cabergoline; Cardiovascular Diseases; Comorbidity; Diabetes Mellitus, Type 2; Dopamine Agonists; Ergolines; Humans; Hypoglycemic Agents; Risk Factors; Treatment Outcome | 2016 |
Pharmacological lactation suppression with D2 receptor agonists and risk of postpartum psychosis: A systematic review.
Topics: Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Lactation; Psychoses, Substance-Induced; Receptors, Dopamine D2; Risk Factors | 2016 |
Dopamine agonists for preventing ovarian hyperstimulation syndrome.
Topics: Abortion, Spontaneous; Administration, Oral; Aminoquinolines; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Ovarian Hyperstimulation Syndrome; Pregnancy; Pregnancy Rate; Randomized Controlled Trials as Topic; Reproductive Techniques, Assisted | 2016 |
Current Medical Strategies in the Prevention of Ovarian Hyperstimulation Syndrome
Topics: Aminoquinolines; Bromocriptine; Buserelin; Cabergoline; Chorionic Gonadotropin; Dopamine Agonists; Ergolines; Estradiol; Estrogens; Female; Fertility Agents, Female; Fertilization in Vitro; Gonadotropin-Releasing Hormone; Humans; Leuprolide; Oocyte Retrieval; Ovarian Hyperstimulation Syndrome; Ovulation Induction; Pregnancy; Pregnancy Rate; Progesterone; Progestins; Triptorelin Pamoate | 2017 |
Cabergoline versus bromocriptine for the treatment of giant prolactinomas: A quantitative and systematic review.
Topics: Adult; Bromocriptine; Cabergoline; Female; Humans; Hydranencephaly; Kidney Diseases; Male; Middle Aged; Prolactin; Prolactinoma; Sex Distribution; Treatment Outcome | 2018 |
Management of Dopamine Agonist-Resistant Prolactinoma.
Topics: Bromocriptine; Cabergoline; Dopamine Agonists; Drug Resistance; Humans; Pituitary Neoplasms; Prolactinoma | 2019 |
Dopamine agonists for preventing ovarian hyperstimulation syndrome.
Topics: Abortion, Spontaneous; Administration, Oral; Aminoquinolines; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Female; Fertilization in Vitro; Humans; Live Birth; Ovarian Hyperstimulation Syndrome; Placebos; Pregnancy; Pregnancy Rate; Randomized Controlled Trials as Topic; Sperm Injections, Intracytoplasmic | 2021 |
Apoplexy of microprolactinomas during pregnancy: report of five cases and review of the literature.
Topics: Adult; Bromocriptine; Cabergoline; Dopamine Agonists; Female; Humans; Pituitary Apoplexy; Pituitary Neoplasms; Pregnancy; Pregnancy Complications; Pregnancy Complications, Neoplastic; Prolactinoma; Tumor Burden; Young Adult | 2021 |
The recurrence of prolactinoma after withdrawal of dopamine agonist: a systematic review and meta-analysis.
Topics: Bromocriptine; Cabergoline; Deprescriptions; Dopamine Agonists; Humans; Neoplasm Recurrence, Local; Pituitary Neoplasms; Prolactinoma | 2021 |
Resistance to Dopamine Agonists in Pituitary Tumors: Molecular Mechanisms.
Topics: ACTH-Secreting Pituitary Adenoma; Adenoma; Aminoquinolines; beta-Arrestins; Bromocriptine; Cabergoline; Dopamine Agonists; Drug Resistance, Neoplasm; Filamins; Growth Hormone-Secreting Pituitary Adenoma; Humans; Lisuride; MicroRNAs; Pergolide; Pituitary Neoplasms; Prolactinoma; Receptors, Dopamine D2 | 2021 |
Therapeutic potential of dopamine agonists in the treatment of type 2 diabetes mellitus.
Topics: Bromocriptine; Cabergoline; Diabetes Mellitus, Type 2; Dopamine Agonists; Humans; Hyperprolactinemia; Parkinson Disease; Restless Legs Syndrome | 2022 |
Treatment of Prolactinoma.
Topics: Bromocriptine; Cabergoline; Dopamine Agonists; Female; Humans; Pituitary Neoplasms; Pregnancy; Prolactinoma; Treatment Outcome | 2022 |
Impulse control disorders in hyperprolactinemic patients on dopamine agonist therapy.
Topics: Bromocriptine; Cabergoline; Disruptive, Impulse Control, and Conduct Disorders; Dopamine Agonists; Humans; Hyperprolactinemia; Male; Pituitary Neoplasms | 2022 |
Metabolic effects of prolactin.
Topics: Bromocriptine; Cabergoline; Dopamine; Dopamine Agonists; Glucose; Humans; Hyperprolactinemia; Lipids; Male; Metabolic Syndrome; Obesity; Prolactin; Receptors, Dopamine; Receptors, Prolactin; Testosterone; Weight Gain | 2022 |
The efficacy and safety of quinagolide in hyperprolactinemia treatment: A systematic review and meta-analysis.
Topics: Aminoquinolines; Bromocriptine; Cabergoline; Drug-Related Side Effects and Adverse Reactions; Humans; Hyperprolactinemia; Pituitary Neoplasms | 2023 |
How to manage intolerance to dopamine agonist in patients with prolactinoma.
Topics: Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Hyperprolactinemia; Pituitary Neoplasms; Prolactinoma | 2023 |
Diagnosis and Management of Pituitary Adenomas: A Review.
Topics: Adenoma; Adrenocorticotropic Hormone; Adult; Bromocriptine; Cabergoline; Child; Female; Human Growth Hormone; Humans; Hypopituitarism; Pituitary Neoplasms; Pregnancy; Prolactinoma | 2023 |
25 trial(s) available for bromocriptine and cabergoline
| Article | Year |
|---|---|
Single dose cabergoline versus bromocriptine in inhibition of puerperal lactation: randomised, double blind, multicentre study. European Multicentre Study Group for Cabergoline in Lactation Inhibition.
Topics: Adult; Bromocriptine; Cabergoline; Dopamine Agents; Double-Blind Method; Drug Administration Schedule; Ergolines; Female; Humans; Lactation; Pregnancy; Prospective Studies | 1991 |
Cabergoline versus bromocriptine in suppression of lactation after cesarean delivery.
Topics: Administration, Oral; Adult; Bromocriptine; Cabergoline; Cesarean Section; Ergolines; Female; Humans; Lactation; Postpartum Period; Prolactin; Single-Blind Method | 1991 |
Prolactin-lowering effect of acute and once weekly repetitive oral administration of cabergoline at two dose levels in hyperprolactinemic patients.
Topics: Adolescent; Adult; Amenorrhea; Bromocriptine; Cabergoline; Clinical Trials as Topic; Ergolines; Female; Humans; Hyperprolactinemia; Kinetics; Male; Middle Aged; Prolactin | 1988 |
[Hyperprolactinemic amenorrhea:treatment with cabergoline versus bromocriptine. Results of a national multicenter randomized double-blind study].
Topics: Adolescent; Adult; Amenorrhea; Bromocriptine; Cabergoline; Dopamine Agonists; Double-Blind Method; Ergolines; Female; France; Humans; Hyperprolactinemia; Middle Aged; Prolactin; Prospective Studies | 1995 |
A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group.
Topics: Adolescent; Adult; Amenorrhea; Bromocriptine; Cabergoline; Dopamine Agents; Double-Blind Method; Ergolines; Female; Humans; Hyperprolactinemia; Middle Aged; Prolactin | 1994 |
Effects of the dopamine agonist cabergoline in patients with prolactinoma intolerant or resistant to bromocriptine.
Topics: Adult; Antineoplastic Agents; Bromocriptine; Cabergoline; Dopamine Agonists; Drug Resistance, Neoplasm; Ergolines; Female; Humans; Male; Middle Aged; Pituitary Neoplasms; Pregnancy; Prolactinoma | 1996 |
Double-blind comparison of cabergoline and bromocriptine in Parkinson's disease patients with motor fluctuations.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Bromocriptine; Cabergoline; Double-Blind Method; Ergolines; Female; Humans; Male; Middle Aged; Movement Disorders; Parkinson Disease | 1996 |
Cabergoline for hyperprolactinemia.
Topics: Abnormalities, Drug-Induced; Bromocriptine; Cabergoline; Costs and Cost Analysis; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Administration Schedule; Ergolines; Female; Humans; Intestinal Absorption; Prolactin | 1997 |
Bone marker and bone density responses to dopamine agonist therapy in hyperprolactinemic males.
Topics: Adult; Aminoquinolines; Biomarkers; Bone and Bones; Bone Density; Bone Diseases, Metabolic; Bone Remodeling; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Humans; Hyperprolactinemia; Male; Middle Aged; Prospective Studies | 1998 |
Cabergoline treatment rapidly improves gonadal function in hyperprolactinemic males: a comparison with bromocriptine.
Topics: Adult; Bromocriptine; Cabergoline; Cohort Studies; Dopamine Agonists; Ergolines; Follow-Up Studies; Hormones; Humans; Hyperprolactinemia; Libido; Male; Penile Erection; Prolactin; Semen; Time Factors | 1998 |
[Treatment of hyperprolactinemic amenorrhea with cabergoline].
Topics: Adolescent; Adult; Amenorrhea; Bromocriptine; Cabergoline; Dopamine Agonists; Double-Blind Method; Drug Tolerance; Ergolines; Female; Humans; Hyperprolactinemia; Prolactin; Treatment Outcome | 1997 |
Study of the change of prolactin and progesterone during dopaminergic agonist treatments in pseudopregnant bitches.
Topics: Animals; Bromocriptine; Cabergoline; Dog Diseases; Dogs; Dopamine Agonists; Ergolines; Female; Placebos; Progesterone; Prolactin; Pseudopregnancy | 2001 |
Comparison of the effects of cabergoline and bromocriptine on prolactin levels in hyperprolactinemic patients.
Topics: Adult; Antineoplastic Agents, Hormonal; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Female; Hormone Antagonists; Humans; Hyperprolactinemia; Male; Middle Aged; Pituitary Neoplasms; Prolactin; Prolactinoma; Treatment Outcome | 2001 |
Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy.
Topics: Adenoma; Adolescent; Adult; Aged; Bromocriptine; Cabergoline; Dopamine Agonists; Drug Resistance; Ergolines; Female; Hormone Antagonists; Humans; Hyperprolactinemia; Hypopituitarism; Magnetic Resonance Imaging; Male; Middle Aged; Pituitary Neoplasms; Prolactin; Radioimmunoassay; Retrospective Studies | 2001 |
Circulating nitric oxide changes throughout the menstrual cycle in healthy women and women affected by pathological hyperprolactinemia on dopamine agonist therapy.
Topics: Adult; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Estradiol; Female; Humans; Hyperprolactinemia; Luteal Phase; Menstrual Cycle; Nitric Oxide; Ovulation; Pituitary Neoplasms; Progesterone; Prolactinoma; Reference Values | 2002 |
Coat colour changes associated with cabergoline administration in bitches.
Topics: Animals; Bromocriptine; Cabergoline; Dog Diseases; Dogs; Dopamine Agonists; Ergolines; Estrous Cycle; Female; Hair Color; Melanocyte-Stimulating Hormones; Pedigree; Pigmentation; Pseudopregnancy | 2003 |
Medical therapy of macroprolactinomas in males: I. Prevalence of hypopituitarism at diagnosis. II. Proportion of cases exhibiting recovery of pituitary function.
Topics: Adrenocorticotropic Hormone; Adult; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Follicle Stimulating Hormone; Humans; Hypopituitarism; Luteinizing Hormone; Male; Middle Aged; Pergolide; Pituitary Function Tests; Pituitary Gland; Pituitary Neoplasms; Prolactin; Prolactinoma; Testosterone; Thyrotropin | 2002 |
Usefulness of switching to cabergoline from other dopamine agonists in patients with advanced Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Bromocriptine; Cabergoline; Ergolines; Humans; Parkinson Disease; Pergolide; Prospective Studies; Treatment Outcome | 2004 |
[Comparative evaluation of effectiveness of treatment of hyperprolactinemia].
Topics: Adenoma; Adolescent; Adult; Bromocriptine; Cabergoline; Dopamine Agonists; Drug Administration Schedule; Ergolines; Female; Humans; Hyperprolactinemia; Ovulation; Pituitary Neoplasms; Treatment Outcome | 2007 |
Quality of life in women with microprolactinoma treated with dopamine agonists.
Topics: Adult; Antineoplastic Agents; Brazil; Bromocriptine; Cabergoline; Case-Control Studies; Cross-Sectional Studies; Dopamine Agonists; Ergolines; Female; Health Status Indicators; Humans; Hyperprolactinemia; Middle Aged; Multivariate Analysis; Pituitary Neoplasms; Prolactin; Prolactinoma; Quality of Life; Reproducibility of Results; Surveys and Questionnaires; Treatment Outcome | 2008 |
Overnight switching from ergot-derived dopamine agonists to pramipexole in patients with Parkinson's disease: an open preliminary trial in Japan.
Topics: Benzothiazoles; Bromocriptine; Cabergoline; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Administration Schedule; Ergolines; Humans; Japan; Outcome Assessment, Health Care; Parkinson Disease; Pergolide; Pramipexole; Severity of Illness Index; Time Factors; Treatment Outcome | 2009 |
Cabergoline versus bromocriptine for symptomatic treatment of premenstrual mastalgia: a randomised, open-label study.
Topics: Adult; Analysis of Variance; Breast; Bromocriptine; Cabergoline; Drug Administration Schedule; Ergolines; Female; Hormone Antagonists; Humans; Middle Aged; Pain; Pain Measurement; Premenstrual Syndrome; Prolactin; Quality of Life; Severity of Illness Index; Treatment Outcome | 2010 |
A comparison of bromocriptine & cabergoline on fertility outcome of hyperprolactinemic infertile women undergoing intrauterine insemination.
Topics: Adult; Bromocriptine; Cabergoline; Ergolines; Female; Humans; Hyperprolactinemia; Infertility, Female; Insemination, Artificial | 2010 |
Evaluation of the efficacy of pramipexole for treating levodopa-induced dyskinesia in patients with Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Benzothiazoles; Bromocriptine; Cabergoline; Dopamine Agonists; Dyskinesia, Drug-Induced; Ergolines; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pergolide; Pramipexole; Receptors, Dopamine D1; Receptors, Dopamine D2; Receptors, Dopamine D3 | 2013 |
Different effects of cabergoline and bromocriptine on metabolic and cardiovascular risk factors in patients with elevated prolactin levels.
Topics: Adult; Blood Glucose; Bromocriptine; Cabergoline; Cardiovascular Diseases; Dopamine Agonists; Ergolines; Female; Humans; Hyperprolactinemia; Insulin Resistance; Insulin-Like Growth Factor I; Lipids; Middle Aged; Prolactin; Risk Factors | 2015 |
122 other study(ies) available for bromocriptine and cabergoline
| Article | Year |
|---|---|
Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes.
Topics: Animals; Antiparkinson Agents; Binding Sites; Binding, Competitive; Cholinergic Antagonists; Cloning, Molecular; Cluster Analysis; Dopamine Agonists; Humans; Rats; Receptor, Muscarinic M1; Receptors, Adrenergic, alpha-1; Receptors, Adrenergic, alpha-2; Receptors, Adrenergic, beta; Receptors, Dopamine D1; Receptors, Dopamine D2; Receptors, Dopamine D3; Receptors, Histamine H1; Receptors, Muscarinic; Receptors, Neurotransmitter; Receptors, Serotonin | 2002 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Pleuropulmonary changes during treatment of Parkinson's disease with a long-acting ergot derivative, cabergoline.
Topics: Bromocriptine; Cabergoline; Dopamine Agents; Ergolines; Humans; Lung Diseases; Male; Middle Aged; Parkinson Disease; Pleural Effusion | 1992 |
Cabergoline in the long-term therapy of hyperprolactinemic disorders.
Topics: Adolescent; Adult; Aged; Bromocriptine; Cabergoline; Drug Resistance; Ergolines; Female; Humans; Hyperprolactinemia; Male; Menstruation Disturbances; Middle Aged; Ovulation; Pituitary Neoplasms; Prolactinoma | 1992 |
In vivo interaction of cabergoline with rat brain dopamine receptors labelled with [3H]N-n-propylnorapomorphine.
Topics: Administration, Oral; Animals; Apomorphine; Brain Chemistry; Bromocriptine; Cabergoline; Dopamine Agents; Dose-Response Relationship, Drug; Ergolines; Female; In Vitro Techniques; Injections, Intravenous; Kinetics; Rats; Rats, Inbred Strains; Receptors, Dopamine | 1990 |
New perspectives in medical management of hyperprolactinemia.
Topics: Adenoma; Bromocriptine; Cabergoline; Delayed-Action Preparations; Empty Sella Syndrome; Ergolines; Female; Humans; Hyperprolactinemia; Male; Pituitary Neoplasms | 1990 |
Effectiveness and tolerability of long term treatment with cabergoline, a new long-lasting ergoline derivative, in hyperprolactinemic patients.
Topics: Adenoma; Adult; Amenorrhea; Bromocriptine; Cabergoline; Dopamine Agents; Ergolines; Female; Humans; Hyperprolactinemia; Pituitary Neoplasms; Prolactin | 1989 |
Inhibitory effect of cabergoline on the development of estrogen-induced prolactin-secreting adenomas of the pituitary.
Topics: Adenoma; Animals; Antineoplastic Agents; Body Weight; Bromocriptine; Cabergoline; DNA, Neoplasm; Ergolines; Estrogens; Female; Mitosis; Pituitary Neoplasms; Prolactin; Rats | 1988 |
Long-lasting prolactin-lowering effect of cabergoline, a new dopamine agonist, in hyperprolactinemic patients.
Topics: Adult; Aged; Blood Pressure; Bromocriptine; Cabergoline; Ergolines; Female; Growth Hormone; Humans; Hyperprolactinemia; Male; Middle Aged; Time Factors | 1986 |
Antitumor activity of FCE 21336, a new prolactin lowering drug, on the MXT mouse mammary carcinoma.
Topics: Animals; Antineoplastic Agents; Bromocriptine; Cabergoline; Dose-Response Relationship, Drug; Ergolines; Female; Mammary Neoplasms, Experimental; Mice; Prolactin | 1985 |
Effect of octreotide on circulating IGF-I chromatographic profile: evidence for an inhibitory action on the formation of the 150-kDa ternary complex.
Topics: Acromegaly; Adult; Bromocriptine; Cabergoline; Carrier Proteins; Ergolines; Growth Hormone; Humans; Insulin-Like Growth Factor Binding Proteins; Insulin-Like Growth Factor I; Insulin-Like Growth Factor II; Middle Aged; Octreotide | 1995 |
In vivo effect of cabergoline, a dopamine agonist, on estrogen-induced rat pituitary tumors.
Topics: Animals; Antineoplastic Agents; Bromocriptine; Cabergoline; Cytoplasmic Granules; Dopamine Agonists; Endoplasmic Reticulum; Ergolines; Estradiol; Female; Microscopy, Electron; Organ Size; Pituitary Neoplasms; Prolactin; Rats; Rats, Inbred F344 | 1995 |
Effect of cabergoline, a dopamine agonist, on estrogen-induced rat pituitary tumors: in vitro culture studies.
Topics: Animals; Antineoplastic Agents; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Estradiol; Female; Pituitary Neoplasms; Prolactin; Rats; Rats, Inbred F344; Tumor Cells, Cultured | 1995 |
X-ray crystal structure and conformational analysis of N-(3-dimethylaminopropyl)-N-(ethylaminocarbonyl)-6-(2-propenyl)er goline -8 beta-carboxamide (Cabergoline): comparison with bromocriptine and lisuride and a hypothesis for its high dopaminergic activi
Topics: Bromocriptine; Cabergoline; Crystallography, X-Ray; Dopamine Agonists; Ergolines; Lisuride; Molecular Conformation; Structure-Activity Relationship | 1995 |
Drenching sweats as an off phenomenon in Parkinson's disease: treatment and relation to plasma levodopa profile.
Topics: Aged; Bromocriptine; Cabergoline; Chorea; Dopamine Agonists; Ergolines; Female; Humans; Levodopa; Male; Middle Aged; Monitoring, Physiologic; Parkinson Disease; Pergolide; Sweating | 1995 |
Cabergoline treated hyperprolactinaemia results in pregnancy in a bromocriptine intolerant patient after seventeen years of infertility.
Topics: Adult; Bromocriptine; Cabergoline; Dopamine Agents; Ergolines; Female; Humans; Hyperprolactinemia; Infertility, Female; Pregnancy | 1994 |
Progress in the management of hyperprolactinemia.
Topics: Amenorrhea; Bromocriptine; Cabergoline; Dopamine Agents; Ergolines; Female; Humans; Hyperprolactinemia | 1994 |
Vaginal cabergoline in the treatment of hyperprolactinemic patients intolerant to oral dopaminergics.
Topics: Adult; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Hyperprolactinemia; Vagina | 1996 |
Differential effects of three dopamine receptor agonists in MPTP-treated monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Bromocriptine; Cabergoline; Dopamine Agonists; Dose-Response Relationship, Drug; Ergolines; Macaca fascicularis; Parkinson Disease, Secondary; Pergolide | 1995 |
Dopamine receptor affinities in vitro and stereotypic activities in vivo of cabergoline in rats.
Topics: Animals; Benzazepines; Binding, Competitive; Bromocriptine; Cabergoline; Dopamine Agonists; Dopamine Antagonists; Ergolines; In Vitro Techniques; Male; Pergolide; Rats; Rats, Sprague-Dawley; Receptors, Dopamine; Receptors, Dopamine D1; Receptors, Dopamine D2; Stereotyped Behavior | 1996 |
Effect of different dopaminergic agents in the treatment of acromegaly.
Topics: Acromegaly; Adult; Aminoquinolines; Bromocriptine; Cabergoline; Delayed-Action Preparations; Dopamine Agonists; Ergolines; Female; Human Growth Hormone; Humans; Male; Middle Aged; Prolactin | 1997 |
Late development of resistance to bromocriptine in a patient with macroprolactinoma.
Topics: Aminoquinolines; Bromocriptine; Cabergoline; Dopamine Agonists; Drug Resistance, Neoplasm; Ergolines; Humans; Male; Middle Aged; Pituitary Neoplasms; Prolactin; Prolactinoma | 1998 |
New hyperprolactinemia and anovulation model in common marmoset (Callithrix jacchus) and effect of cabergoline.
Topics: Animals; Anovulation; Bromocriptine; Cabergoline; Callithrix; Disease Models, Animal; Dopamine Agonists; Dopamine Antagonists; Ergolines; Estradiol; Female; Hyperprolactinemia; Menstrual Cycle; Progesterone; Prolactin; Sulpiride; Time Factors | 1999 |
Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients.
Topics: Adenoma; Adult; Antineoplastic Agents; Bromocriptine; Cabergoline; Dopamine Agonists; Drug Resistance; Drug Tolerance; Ergolines; Female; Humans; Hyperprolactinemia; Male; Middle Aged; Pituitary Neoplasms; Pregnancy; Retrospective Studies; Sex Characteristics | 1999 |
Prolactinomas in adolescents: persistent bone loss after 2 years of prolactin normalization.
Topics: Adolescent; Adult; Aminoquinolines; Analysis of Variance; Biomarkers; Bone Density; Bone Remodeling; Bromocriptine; Cabergoline; Case-Control Studies; Collagen; Collagen Type I; Dopamine Agonists; Ergolines; Female; Femur Neck; Humans; Longitudinal Studies; Lumbar Vertebrae; Male; Middle Aged; Osteocalcin; Osteoporosis; Peptides; Pituitary Neoplasms; Prolactinoma; Regression Analysis | 2000 |
Comparative effects of repeated administration of dopamine agonists on circling behavior in rats.
Topics: Animals; Benzothiazoles; Brain; Bromocriptine; Cabergoline; Dopamine Agonists; Drug Administration Schedule; Ergolines; Indoles; Male; Motor Activity; Oxidopamine; Parkinsonian Disorders; Pergolide; Pramipexole; Rats; Rats, Sprague-Dawley; Reaction Time; Receptors, Dopamine D1; Receptors, Dopamine D2; Thiazoles | 2000 |
Use of the dopamine agonists bromocriptine and cabergoline in the management of risperidone-induced hyperprolactinemia in patients with psychotic disorders.
Topics: Adult; Antipsychotic Agents; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Hyperprolactinemia; Hypogonadism; Male; Middle Aged; Prolactin; Psychotic Disorders; Risperidone | 2000 |
Treatment versus no treatment of transient hyperprolactinemia in patients undergoing intracytoplasmic sperm injection programs.
Topics: Adult; Bromocriptine; Cabergoline; Chorionic Gonadotropin; Dopamine Agonists; Embryo Transfer; Ergolines; Estradiol; Female; Follicle Stimulating Hormone; Gonadotropin-Releasing Hormone; Hormone Antagonists; Humans; Hyperprolactinemia; Luteolytic Agents; Oocytes; Prolactin; Retrospective Studies; Sperm Injections, Intracytoplasmic; Treatment Outcome; Triptorelin Pamoate | 2000 |
Pituitary adenomas in childhood and adolescence. Clinical analysis of 10 cases.
Topics: Acromegaly; Adenoma; Adolescent; Amenorrhea; Bromocriptine; Cabergoline; Child; Ergolines; Female; Headache; Human Growth Hormone; Humans; Male; Neoplasm Recurrence, Local; Octreotide; Pituitary Neoplasms; Prolactinoma; Puberty, Delayed; Radiotherapy; Treatment Outcome; Vision Disorders; Visual Fields | 2001 |
Laboratory and clinical experience in 55 patients with macroprolactinemia identified by a simple polyethylene glycol precipitation method.
Topics: Adult; Bromocriptine; Cabergoline; Cohort Studies; Ergolines; Female; Fertility; Headache; Humans; Magnetic Resonance Imaging; Medical Records; Menstruation; Menstruation Disturbances; Middle Aged; Pituitary Gland; Polyethylene Glycols; Prolactin; Tomography, X-Ray Computed | 2001 |
Successful treatment of a large macroprolactinoma with cabergoline during pregnancy.
Topics: Adult; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Magnetic Resonance Imaging; Pituitary Neoplasms; Pregnancy; Pregnancy Complications, Neoplastic; Prolactinoma | 2001 |
The novel use of very high doses of cabergoline and a combination of testosterone and an aromatase inhibitor in the treatment of a giant prolactinoma.
Topics: Adult; Anastrozole; Aromatase Inhibitors; Bromocriptine; Cabergoline; Dopamine Agonists; Enzyme Inhibitors; Ergolines; Hormone Replacement Therapy; Humans; Magnetic Resonance Imaging; Male; Nitriles; Pituitary Neoplasms; Prolactin; Prolactinoma; Sexual Dysfunction, Physiological; Testosterone; Treatment Outcome; Triazoles | 2002 |
Prolactinomas, dopamine agonists and headache: two case reports.
Topics: Adult; Amenorrhea; Anti-Inflammatory Agents, Non-Steroidal; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Female; Headache; Humans; Indomethacin; Magnetic Resonance Imaging; Pituitary Neoplasms; Prolactin; Prolactinoma; Radiography | 2003 |
Effects of dopamine agonists bromocriptine, pergolide, cabergoline, and SKF-38393 on GDNF, NGF, and BDNF synthesis in cultured mouse astrocytes.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Astrocytes; Blotting, Northern; Brain-Derived Neurotrophic Factor; Bromocriptine; Cabergoline; Dopamine Agonists; Dose-Response Relationship, Drug; Enzyme-Linked Immunosorbent Assay; Ergolines; Glial Cell Line-Derived Neurotrophic Factor; Mice; Mice, Inbred ICR; Nerve Growth Factor; Nerve Growth Factors; Pergolide; Receptors, Dopamine D1; Receptors, Dopamine D2; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Time Factors | 2003 |
[Clinical and therapeutic aspects of prolactinoma in men].
Topics: Adolescent; Adult; Age of Onset; Biomarkers; Bromocriptine; Cabergoline; Chi-Square Distribution; Dopamine Agonists; Ergolines; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Staging; Pituitary Neoplasms; Prolactin; Prolactinoma; Statistics, Nonparametric; Treatment Outcome | 2003 |
Prolactinoma presenting as painful postganglionic Horner syndrome.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain; Bromocriptine; Cabergoline; Carotid Arteries; Dopamine Agonists; Ergolines; Horner Syndrome; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Migraine Disorders; Neoplasm Recurrence, Local; p-Hydroxyamphetamine; Pituitary Neoplasms; Prolactin; Prolactinoma; Remission Induction | 2004 |
Switching from ergot to nonergot dopamine agonists in Parkinson's disease: a clinical series and five-drug dose conversion table.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Antiparkinson Agents; Benzothiazoles; Bromocriptine; Cabergoline; Domperidone; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Ergolines; Ergot Alkaloids; Feasibility Studies; Female; Follow-Up Studies; Humans; Indoles; Levodopa; Male; Middle Aged; Parkinson Disease; Pergolide; Pramipexole; Therapeutic Equivalency; Thiazoles | 2004 |
Cardiopulmonary complications of ergot-derivative dopamine agonists.
Topics: Antipsychotic Agents; Bromocriptine; Cabergoline; Dopamine Agonists; Dose-Response Relationship, Drug; Ergolines; Heart Valve Diseases; Humans; Hyperprolactinemia; Pergolide; Pulmonary Fibrosis; Risperidone | 2004 |
Valvular heart disease and fibrotic reactions may be related to ergot dopamine agonists, but non-ergot agonists may also not be spared.
Topics: Aortic Valve; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Fibrosis; Heart Valve Diseases; Humans; Parkinson Disease; Pergolide | 2004 |
Nelson's syndrome: complete remission with cabergoline but not with bromocriptine or cyproheptadine treatment.
Topics: Adenoma; Adrenalectomy; Adrenocorticotropic Hormone; Adult; Bromocriptine; Cabergoline; Cyproheptadine; Dopamine Agonists; Ergolines; Female; Hormone Replacement Therapy; Humans; Magnetic Resonance Imaging; Nelson Syndrome; Pituitary Neoplasms | 2004 |
Dopamine agonist treatment before and after the birth reduces prolactin concentration but does not impair paternal responsiveness in Djungarian hamsters, Phodopus campbelli.
Topics: Animals; Bromocriptine; Cabergoline; Cricetinae; Dopamine Agonists; Ergolines; Female; Male; Parturition; Paternal Behavior; Phodopus; Pregnancy; Prolactin; Receptors, Dopamine D1; Receptors, Dopamine D2 | 2005 |
Effectiveness of adding dopamine agonist therapy to long-acting somatostatin analogues in the management of acromegaly.
Topics: Acromegaly; Adult; Aged; Aged, 80 and over; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Female; Human Growth Hormone; Humans; Insulin-Like Growth Factor I; Male; Middle Aged; Prolactin; Retrospective Studies; Somatostatin | 2005 |
The clinical characteristics of headache in patients with pituitary tumours.
Topics: Adenoma; Adult; Aminoquinolines; Antineoplastic Agents, Hormonal; Bromocriptine; Cabergoline; Disability Evaluation; Dopamine Agonists; Ergolines; Female; Headache; Humans; Male; Migraine Disorders; Octreotide; Peptides, Cyclic; Pituitary Neoplasms; Severity of Illness Index; Somatostatin; Time Factors | 2005 |
The use of high-dose daily cabergoline in an adolescent patient with macroprolactinoma.
Topics: Bromocriptine; Cabergoline; Child; Dopamine Agonists; Ergolines; Humans; Magnetic Resonance Imaging; Male; Pituitary Neoplasms; Prolactinoma; Treatment Outcome | 2005 |
Long-term remission following withdrawal of dopamine agonist therapy in subjects with microprolactinomas.
Topics: Adolescent; Adult; Antineoplastic Agents; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Male; Middle Aged; Pituitary Neoplasms; Prolactinoma; Recurrence; Remission Induction; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome | 2005 |
Surgical outcomes in hyporesponsive prolactinomas: analysis of patients with resistance or intolerance to dopamine agonists.
Topics: Adult; Aged; Bromocriptine; Cabergoline; Dopamine Agonists; Drug Resistance; Ergolines; Female; Humans; Hyperprolactinemia; Male; Middle Aged; Pergolide; Pituitary Neoplasms; Prolactin; Prolactinoma; Remission Induction; Retrospective Studies; Treatment Outcome | 2005 |
Potential for long-term remission of microprolactinoma after withdrawal of dopamine-agonist therapy.
Topics: Adolescent; Adult; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Male; Middle Aged; Pituitary Neoplasms; Prolactin; Prolactinoma | 2006 |
Clinical presentation and response to therapy in patients with massive prolactin hypersecretion.
Topics: Adult; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Humans; Hyperprolactinemia; Magnetic Resonance Imaging; Male; Pituitary Neoplasms; Prolactin; Prolactinoma; Testosterone | 2007 |
Growth hormone excess with onset in adolescence: clinical appearance and long-term treatment outcome.
Topics: Adolescent; Adult; Antineoplastic Agents, Hormonal; Body Height; Body Mass Index; Bromocriptine; Cabergoline; Combined Modality Therapy; Ergolines; Female; Growth Hormone; Growth Hormone-Secreting Pituitary Adenoma; Headache; Hormone Antagonists; Humans; Insulin Resistance; Insulin-Like Growth Factor I; Male; Menstruation Disturbances; Octreotide; Peptides, Cyclic; Pituitary Neoplasms; Retrospective Studies; Somatostatin; Treatment Outcome | 2007 |
Prolactin and autoimmune diseases in humans.
Topics: Aminoquinolines; Animals; Arthritis, Rheumatoid; Autoimmune Diseases; Bromocriptine; Cabergoline; Cyclosporine; Dopamine Agonists; Double-Blind Method; Drug Therapy, Combination; Ergolines; Female; Humans; Hyperprolactinemia; Immunosuppressive Agents; Lupus Erythematosus, Systemic; Male; Mice; Mice, Knockout; Penicillamine; Prednisone; Prolactin; Rats; Receptors, Prolactin | 2007 |
Dopaminergic treatment of nonfunctioning pituitary adenomas.
Topics: Adenoma; Bromocriptine; Cabergoline; Dopamine Agents; Dopamine Agonists; Ergolines; Humans; Pituitary Neoplasms; Prolactin | 2007 |
Remarkable effects of cabergoline in a patient with huge prolactinoma resistant to high-dose bromocriptine: case report.
Topics: Adult; Antineoplastic Agents; Bromocriptine; Cabergoline; Dopamine Agonists; Drug Resistance, Neoplasm; Ergolines; Humans; Male; Pituitary Neoplasms; Prolactinoma; Treatment Outcome | 2008 |
The frequency of cardiac valvular regurgitation in Parkinson's disease.
Topics: Aged; Aortic Valve Insufficiency; Azepines; Benzothiazoles; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Male; Mitral Valve Insufficiency; Parkinson Disease; Pergolide; Pramipexole; Prevalence | 2008 |
Clinical profile and long term follow up of children and adolescents with prolactinomas.
Topics: Adolescent; Amenorrhea; Bromocriptine; Cabergoline; Child; Dopamine Agonists; Ergolines; Female; Galactorrhea; Humans; Male; Pregnancy; Prolactin; Prolactinoma; Retrospective Studies; Treatment Outcome; Young Adult | 2009 |
High risk factors for valvular heart disease from dopamine agonists in patients with Parkinson's disease.
Topics: Age Factors; Aged; Benzothiazoles; Bromocriptine; Cabergoline; Case-Control Studies; Dopamine Agonists; Echocardiography; Ergolines; Female; Heart Valve Diseases; Humans; Hypertension; Male; Parkinson Disease; Pergolide; Pramipexole; Risk Factors | 2009 |
Cardiac and noncardiac fibrotic reactions caused by ergot-and nonergot-derived dopamine agonists.
Topics: Aged; Aged, 80 and over; Apomorphine; Benzothiazoles; Bromocriptine; Cabergoline; Databases, Factual; Dopamine Agonists; Endomyocardial Fibrosis; Ergolines; Female; Fibrosis; Heart Valve Diseases; Humans; Indoles; Male; Middle Aged; Pergolide; Pericarditis; Pleural Diseases; Pramipexole; Pulmonary Fibrosis; Retroperitoneal Fibrosis; Tetrahydronaphthalenes; Thiophenes; United States | 2009 |
Dopamine agonists and hyperprolactinaemia.
Topics: Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Heart Valve Diseases; Humans; Hyperprolactinemia | 2009 |
Dopamine agonists, Dopplers and doubt: cabergoline-associated cardiac valvulopathy.
Topics: Antiparkinson Agents; Bromocriptine; Cabergoline; Case-Control Studies; Cross-Sectional Studies; Dopamine Agonists; Ergolines; Female; Heart Valve Diseases; Humans; Hyperprolactinemia; Male; Parkinson Disease; Pergolide; Prolactin; Serotonin 5-HT2 Receptor Agonists; Ultrasonography | 2009 |
Non-surgical management of cystic prolactinomas.
Topics: Adult; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Follow-Up Studies; Gadolinium; Hormones; Humans; Magnetic Resonance Imaging; Male; Pituitary Neoplasms; Prolactinoma; Retrospective Studies; Young Adult | 2009 |
Comparative efficacy of bromocriptine, cabergoline and thyroxine in inducing oestrus in bitches.
Topics: Animals; Bromocriptine; Cabergoline; Dogs; Ergolines; Estrous Cycle; Female; Fertilization; Hormone Antagonists; Litter Size; Progesterone; Prolactin; Thyroxine | 2010 |
Management of prolactinomas in Brazil: an electronic survey.
Topics: Brazil; Bromocriptine; Cabergoline; Data Collection; Dopamine Agonists; Ergolines; Female; Humans; Pregnancy; Prolactinoma | 2010 |
Individualized high-dose cabergoline therapy for hyperprolactinemic infertility in women with micro- and macroprolactinomas.
Topics: Adult; Birth Weight; Bromocriptine; Cabergoline; Cohort Studies; Dopamine Agonists; Drug Resistance; Ergolines; Female; Humans; Hyperprolactinemia; Infertility, Female; Magnetic Resonance Imaging; Pituitary Neoplasms; Pregnancy; Pregnancy Complications; Pregnancy Outcome; Progesterone; Prolactin; Prolactinoma | 2010 |
Comparison of cabergoline and bromocriptine in patients with asymptomatic incidental hyperprolactinemia undergoing ICSI-ET.
Topics: Adult; Bromocriptine; Cabergoline; Databases, Factual; Dopamine Agonists; Ergolines; Female; Humans; Hyperprolactinemia; Infertility, Female; Pregnancy; Pregnancy Rate; Retrospective Studies; Sperm Injections, Intracytoplasmic; Treatment Outcome | 2010 |
BMI and metabolic profile in patients with prolactinoma before and after treatment with dopamine agonists.
Topics: Adult; Aftercare; Aged; Blood Glucose; Body Composition; Body Mass Index; Body Weight; Bromocriptine; Cabergoline; Cholesterol, HDL; Cholesterol, LDL; Dopamine Agonists; Ergolines; Female; Humans; Insulin; Insulin Resistance; Leptin; Male; Metabolic Syndrome; Metabolome; Middle Aged; Obesity; Prevalence; Prolactinoma; Waist Circumference; Weight Gain; Young Adult | 2011 |
Effect of dopaminergic drug treatment on surgical findings in prolactinomas.
Topics: Adenoma; Adolescent; Adult; Aged; Bromocriptine; Cabergoline; Child; Dopamine Agents; Ergolines; Female; Humans; Male; Middle Aged; Pituitary Neoplasms; Prolactinoma; Retrospective Studies; Young Adult | 2011 |
Disorganized schizophrenia does not deteriorate with dopamine agonists cabergoline and bromocriptine used for ablactation.
Topics: Adult; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Lactation; Mastitis; Schizophrenia, Disorganized | 2011 |
Pituitary tumors: cabergoline versus bromocriptine: a meta-analysis?
Topics: Antineoplastic Agents; Bromocriptine; Cabergoline; Ergolines; Humans; Meta-Analysis as Topic; Pituitary Neoplasms; Treatment Outcome | 2011 |
Long term follow-up of patients with prolactinomas and outcome of dopamine agonist withdrawal: a single center experience.
Topics: Adolescent; Adult; Aged; Aminoquinolines; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Female; Follow-Up Studies; Humans; Male; Middle Aged; Prolactinoma; Treatment Outcome; Young Adult | 2012 |
A comparison of cabergoline and bromocriptine on the risk of valvular heart disease in patients with prolactinomas.
Topics: Adult; Bromocriptine; Cabergoline; Dopamine Agonists; Echocardiography; Ergolines; Female; Heart Valve Diseases; Humans; Male; Middle Aged; Prolactinoma | 2012 |
[Prescription of ergot derivatives for lactation inhibition in France: Current practices].
Topics: Bromocriptine; Cabergoline; Dihydroergocryptine; Dopamine Agonists; Ergolines; Ergot Alkaloids; Female; France; Humans; Lactation; Lisuride; Practice Patterns, Physicians'; Prolactin; Surveys and Questionnaires | 2012 |
No clinically significant valvular regurgitation in long-term cabergoline treatment for prolactinoma.
Topics: Adolescent; Adult; Antineoplastic Agents; Bromocriptine; Cabergoline; Cross-Sectional Studies; Echocardiography; Ergolines; Female; Humans; Male; Middle Aged; Prolactinoma; Retrospective Studies; Tricuspid Valve Insufficiency; Young Adult | 2012 |
Increased prevalence of subclinical cardiac valve fibrosis in patients with prolactinomas on long-term bromocriptine and cabergoline treatment.
Topics: Adult; Antineoplastic Agents; Bromocriptine; Cabergoline; Case-Control Studies; Dopamine Agonists; Echocardiography; Ergolines; Female; Fibrosis; Heart Valve Diseases; Heart Valves; Humans; Male; Middle Aged; Pituitary Neoplasms; Prevalence; Prolactinoma; Prospective Studies | 2012 |
[Gender effect on cardiomyopathy].
Topics: Bromocriptine; Cabergoline; Cardiomyopathies; Cardiomyopathy, Dilated; Cardiomyopathy, Hypertrophic; Cardiomyopathy, Restrictive; Dopamine Agonists; Ergolines; Evidence-Based Medicine; Female; Genetic Counseling; Humans; Phenotype; Pregnancy; Pregnancy Complications, Cardiovascular; Prognosis; Prolactin; Risk Assessment; Risk Factors; Sex Factors; Treatment Outcome | 2012 |
Optimal effective doses of cabergoline and bromocriptine and valvular leasions in men with prolactinomas.
Topics: Adult; Aged; Bromocriptine; Cabergoline; Dopamine Agonists; Dose-Response Relationship, Drug; Ergolines; Female; Heart Valve Diseases; Humans; Male; Middle Aged; Pituitary Neoplasms; Prevalence; Prolactinoma; Retrospective Studies; Risk Factors; Ultrasonography; Young Adult | 2012 |
Medically treated prolactin-secreting pituitary adenomas: when should we operate?
Topics: Adult; Antineoplastic Agents; Bromocriptine; Cabergoline; Ergolines; Female; Hormone Antagonists; Humans; Magnetic Resonance Imaging; Male; Pituitary Neoplasms; Postmenopause; Premenopause; Prolactinoma; Prospective Studies; Retrospective Studies; Sphenoid Bone; Time Factors; Treatment Failure | 2013 |
Real-world comorbidities and treatment patterns of patients with acromegaly in two large US health plan databases.
Topics: Acromegaly; Adult; Bromocriptine; Cabergoline; Databases, Factual; Ergolines; Female; Human Growth Hormone; Humans; Male; Middle Aged; Octreotide; Peptides, Cyclic; Retrospective Studies; Somatostatin; United States | 2013 |
Short-term pharmacological suppression of the hyperprolactinemia of infertile hCG-overproducing female mice persistently restores their fertility.
Topics: Animals; Bromocriptine; Cabergoline; Chorionic Gonadotropin; Disease Models, Animal; Ergolines; Female; Fertility; Gene Expression Regulation; Humans; Hyperprolactinemia; Infertility; Mice; Mice, Transgenic; Ovulation; Phenotype; Time Factors | 2012 |
Risk of thromboembolic events in patients with prolactinomas compared with patients with nonfunctional pituitary adenomas.
Topics: Adult; Antineoplastic Agents; Bromocriptine; Cabergoline; Ergolines; Female; Humans; Male; Middle Aged; Pergolide; Pituitary Neoplasms; Prolactin; Prolactinoma; Retrospective Studies; Thromboembolism; Young Adult | 2013 |
Hyperprolactinemia in children: clinical features and long-term results.
Topics: Adolescent; Bromocriptine; Cabergoline; Child; Combined Modality Therapy; Ergolines; Female; Hormone Antagonists; Humans; Hyperprolactinemia; Pituitary Neoplasms; Prolactinoma; Retrospective Studies; Treatment Outcome | 2012 |
[Visual outcome in patients with macroprolactinoma treated with dopamine agonists].
Topics: Adolescent; Adult; Bromocriptine; Cabergoline; Child; Dopamine Agonists; Ergolines; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Prolactinoma; Retrospective Studies; Vision Disorders; Visual Acuity; Visual Fields; Young Adult | 2013 |
Occlusal treatment with bite splint improves dyskinesia in Parkinson's disease patient: a case report.
Topics: Activities of Daily Living; Antiparkinson Agents; Bromocriptine; Cabergoline; Clonidine; Dyskinesias; Ergolines; Female; Hand Strength; Humans; Levodopa; Middle Aged; Motor Skills; Occlusal Splints; Parkinson Disease; Posture | 2013 |
[Inhibition of lactation: end to the bromocriptin, long life to the carbergolin?].
Topics: Bromocriptine; Cabergoline; Cardiovascular Diseases; Ergolines; Female; France; Hormone Antagonists; Humans; Lactation | 2014 |
Women with prolactinomas presented at the postmenopausal period.
Topics: Aged; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Female; Follicle Stimulating Hormone; Humans; Hyperprolactinemia; Luteinizing Hormone; Middle Aged; Pituitary Neoplasms; Postmenopause; Prolactin; Prolactinoma; Retrospective Studies; Treatment Outcome | 2014 |
Young female with acromegaloid features and pituitary macroadenoma: what is your diagnosis?
Topics: Acanthosis Nigricans; Acromegaly; Adult; Bromocriptine; Cabergoline; Diagnosis, Differential; Ergolines; Female; Gastrointestinal Diseases; Hirsutism; Human Growth Hormone; Humans; Hyperprolactinemia; Insulin; Insulin Resistance; Insulin-Like Growth Factor I; Pituitary Neoplasms; Pregnancy; Pregnancy Complications; Pregnancy Complications, Neoplastic; Prognathism; Prolactinoma | 2014 |
A case of iatrogenic severe mitral regurgitation.
Topics: Antineoplastic Agents; Bromocriptine; Cabergoline; Drug Therapy, Combination; Ergolines; Heart Valve Prosthesis; Heart Valve Prosthesis Implantation; Hormone Antagonists; Humans; Male; Middle Aged; Mitral Valve Insufficiency; Pituitary Neoplasms; Prolactinoma; Treatment Outcome | 2013 |
Comparison of efficacy of bromocriptine and cabergoline to GnRH agonist in a rat endometriosis model.
Topics: Adult; Animals; Antineoplastic Agents; Bromocriptine; Cabergoline; Disease Models, Animal; Dopamine Agonists; Endometriosis; Endometrium; Ergolines; Female; Gonadotropin-Releasing Hormone; Humans; Laparotomy; Leuprolide; Prospective Studies; Random Allocation; Rats; Rats, Wistar; Triptorelin Pamoate | 2015 |
Retrospective comparison of cabergoline and bromocriptine effects in hyperprolactinemia: a single center experience.
Topics: Adolescent; Adult; Aged; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Hyperprolactinemia; Male; Middle Aged; Retrospective Studies; Treatment Outcome; Young Adult | 2015 |
Treatment outcome results from the Bulgarian Acromegaly Database: adjuvant dopamine agonist therapy is efficient in less than one fifth of non-irradiated patients.
Topics: Acromegaly; Adolescent; Adult; Aged; Bromocriptine; Bulgaria; Cabergoline; Child; Databases, Factual; Dopamine Agonists; Ergolines; Female; Follow-Up Studies; Humans; Male; Middle Aged; Radiotherapy; Remission Induction; Retrospective Studies; Somatostatin | 2015 |
[Pituitary apoplexy in a pregnant woman with cystic microprolactinoma].
Topics: Adult; Bromocriptine; Cabergoline; Combined Modality Therapy; Contraindications; Dopamine Agonists; Drug Substitution; Ergolines; Female; Headache; Hormone Replacement Therapy; Humans; Hydrocortisone; Hypophysectomy; Infant, Newborn; Male; Pituitary Apoplexy; Pituitary Neoplasms; Pregnancy; Pregnancy Complications; Pregnancy Complications, Neoplastic; Prolactinoma; Thyroxine; Vision Disorders | 2015 |
Different Effects of Metformin on the Hypothalamic-Pituitary-Thyroid Axis in Bromocriptine- and Cabergoline-treated Patients with Hashimoto's Thyroiditis and Glucose Metabolism Abnormalities.
Topics: Adult; Bromocriptine; Cabergoline; Ergolines; Female; Glucose Metabolism Disorders; Hashimoto Disease; Humans; Hypothalamo-Hypophyseal System; Metformin; Middle Aged; Thyroid Gland | 2015 |
Cost-Effectiveness Analysis of Microscopic and Endoscopic Transsphenoidal Surgery Versus Medical Therapy in the Management of Microprolactinoma in the United States.
Topics: Adult; Aged; Bromocriptine; Cabergoline; Cost-Benefit Analysis; Decision Support Techniques; Decision Trees; Ergolines; Female; Health Care Costs; Hormone Antagonists; Humans; Hyperprolactinemia; Life Expectancy; Male; Medicare; Microsurgery; Middle Aged; Monte Carlo Method; Neuroendoscopy; Pituitary Neoplasms; Prolactinoma; Quality-Adjusted Life Years; Sphenoid Sinus; Time Factors; Treatment Outcome; United States | 2016 |
Inhibiting the onset of lactation. Is cabergoline an alternative to bromocriptine?
Topics: Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Europe; Female; France; Humans; Lactation | 2015 |
Withdrawal of dopamine agonist therapy in prolactinomas: In which patients and when?
Topics: Adolescent; Adult; Aged; Bromocriptine; Cabergoline; Deprescriptions; Dopamine Agonists; Ergolines; Female; Humans; Hyperprolactinemia; Male; Middle Aged; Neoplasm Recurrence, Local; Patient Selection; Pituitary Neoplasms; Prolactin; Prolactinoma; Retrospective Studies; Time Factors; Tumor Burden; Young Adult | 2016 |
Prolactinomas: evolution after menopause.
Topics: Adenoma; Adult; Bromocriptine; Cabergoline; Disease Progression; Dopamine Agonists; Ergolines; Female; Humans; Menopause; Middle Aged; Pituitary Neoplasms; Prolactin; Prolactinoma; Retrospective Studies; Treatment Outcome; Withholding Treatment | 2016 |
Giant prolactinomas larger than 60 mm in size: a cohort of massive and aggressive prolactin-secreting pituitary adenomas.
Topics: Adolescent; Adult; Antineoplastic Agents; Bromocriptine; Cabergoline; Child; Ergolines; Female; Galactorrhea; Headache; Hormone Antagonists; Humans; Male; Middle Aged; Neurosurgical Procedures; Pituitary Neoplasms; Prolactinoma; Sexual Dysfunction, Physiological; Treatment Outcome; Tumor Burden; Vision Disorders; Young Adult | 2016 |
Treatment of clinically nonfunctioning pituitary adenomas with dopamine agonists.
Topics: Adenoma; Adult; Aged; Bromocriptine; Cabergoline; Disease Progression; Dopamine Agonists; Ergolines; Female; Humans; Immunohistochemistry; Magnetic Resonance Imaging; Male; Middle Aged; Pituitary Neoplasms; Receptors, Dopamine; Receptors, Estrogen; Treatment Outcome | 2016 |
Dopa-testotoxicosis: disruptive hypersexuality in hypogonadal men with prolactinomas treated with dopamine agonists.
Topics: Adult; Aged; Aminoquinolines; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Humans; Hypogonadism; Male; Middle Aged; Pituitary Neoplasms; Prolactinoma; Retrospective Studies; Sexual Dysfunction, Physiological | 2017 |
SURGICAL OUTCOMES OF PROLACTINOMAS IN RECENT ERA: RESULTS OF A HETEROGENOUS GROUP.
Topics: Adult; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neurosurgical Procedures; Pituitary Neoplasms; Prolactinoma; Remission Induction; Retrospective Studies; Treatment Failure; Treatment Outcome; Tumor Burden; Young Adult | 2017 |
10-year follow-up study comparing primary medical vs. surgical therapy in women with prolactinomas.
Topics: Adult; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Female; Follow-Up Studies; Humans; Middle Aged; Pituitary Gland; Pituitary Neoplasms; Prolactin; Prolactinoma; Retrospective Studies; Treatment Outcome; Young Adult | 2017 |
Macroprolactinomas and Nonfunctioning Pituitary Adenomas and Pregnancy Outcomes.
Topics: Adenoma; Adult; Amenorrhea; Antineoplastic Agents; Bromocriptine; Cabergoline; Case-Control Studies; Cesarean Section; Dopamine Agonists; Ergolines; Female; Galactorrhea; Humans; Incidence; Pituitary Neoplasms; Pre-Eclampsia; Preconception Care; Pregnancy; Pregnancy Complications, Neoplastic; Premature Birth; Prolactinoma; Prospective Studies; Stillbirth; United Kingdom; Vision Disorders; Young Adult | 2017 |
MRI follow-up is unnecessary in patients with macroprolactinomas and long-term normal prolactin levels on dopamine agonist treatment.
Topics: Adult; Aminoquinolines; Belgium; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Female; Follow-Up Studies; France; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Pituitary Neoplasms; Prolactin; Prolactinoma; Retrospective Studies | 2017 |
Prolactinoma management: predictors of remission and recurrence after dopamine agonists withdrawal.
Topics: Adolescent; Adult; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Male; Middle Aged; Prolactin; Prolactinoma; Retrospective Studies; Young Adult | 2017 |
Pregnancy and Tumor Outcomes in Women with Prolactinoma.
Topics: Adult; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Hyperprolactinemia; Outcome Assessment, Health Care; Pituitary Neoplasms; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Prolactinoma; Retrospective Studies; Young Adult | 2017 |
Best candidates for dopamine agonist withdrawal in patients with prolactinomas.
Topics: Adolescent; Adult; Aged; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Prolactinoma; Retrospective Studies; Young Adult | 2017 |
The efficacy of medical treatment in patients with acromegaly in clinical practice.
Topics: Acromegaly; Adenoma; Adult; Antineoplastic Agents; Bromocriptine; Cabergoline; Cohort Studies; Dopamine Agonists; Drug Resistance, Neoplasm; Ergolines; Female; Follow-Up Studies; Growth Hormone-Secreting Pituitary Adenoma; Hospitals, University; Human Growth Hormone; Humans; Insulin-Like Growth Factor I; Male; Middle Aged; Neoplasm Grading; Republic of Korea; Retrospective Studies; Somatostatin; Tumor Burden | 2018 |
Failure of a second temozolomide cycle in a patient with a prolactin-secreting pituitary carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Bromocriptine; Cabergoline; Combined Modality Therapy; Dacarbazine; Drug Substitution; Ergolines; Fatal Outcome; Headache; Humans; Hyperprolactinemia; Liver Neoplasms; Male; Neoplasm Recurrence, Local; Pituitary Neoplasms; Prolactin; Prolactinoma; Proton Therapy; Temozolomide | 2017 |
The Expression of Dopamine Receptors Gene and their Potential Role in Targeting Breast Cancer Cells with Selective Agonist and Antagonist Drugs. Could it be the Novel Insight to Therapy?
Topics: Adult; Apoptosis; Breast Neoplasms; Bromocriptine; Cabergoline; Cell Line, Tumor; Cell Proliferation; Dopamine; Dopamine Agonists; Dopamine Antagonists; Female; Gene Expression Regulation, Neoplastic; Humans; Leukocytes, Mononuclear; Middle Aged; Neoplasm Staging; Receptors, Dopamine; Receptors, Estrogen; Receptors, Progesterone; Remoxipride | 2019 |
Impact of menopause on outcomes in prolactinomas after dopamine agonist treatment withdrawal.
Topics: Adolescent; Adult; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Menopause; Postmenopause; Prolactin; Prolactinoma; Retrospective Studies; Withholding Treatment; Young Adult | 2018 |
Cabergoline for the treatment of bromocriptine-resistant invasive giant prolactinomas.
Topics: Adolescent; Adult; Bromocriptine; Cabergoline; Drug Resistance, Neoplasm; Female; Humans; Hyperprolactinemia; Male; Middle Aged; Neoplasm Invasiveness; Pituitary Neoplasms; Prolactin; Prolactinoma; Retrospective Studies; Treatment Failure; Tumor Burden; Young Adult | 2018 |
Bromocriptine and cabergoline induce cell death in prolactinoma cells via the ERK/EGR1 and AKT/mTOR pathway respectively.
Topics: Amino Acid Chloromethyl Ketones; Animals; Apoptosis; Bromocriptine; Cabergoline; Cell Line, Tumor; Early Growth Response Protein 1; Extracellular Signal-Regulated MAP Kinases; Female; Mice; Mice, Nude; Microtubule-Associated Proteins; Pituitary Neoplasms; Prolactinoma; Proto-Oncogene Proteins c-akt; Rats; RNA Interference; RNA, Small Interfering; Signal Transduction; TOR Serine-Threonine Kinases | 2019 |
Radiographic and Hormonal Regression in Prolactinomas: An Analysis of Treatment Failure.
Topics: Adult; Bromocriptine; Cabergoline; Disease Progression; Dopamine Agonists; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Pituitary Neoplasms; Prolactin; Prolactinoma; Sex Factors; Treatment Failure; Tumor Burden | 2019 |
Development of a novel patient-reported measure for acromegaly: the Acro-TSQ.
Topics: Acromegaly; Adult; Bromocriptine; Cabergoline; Female; Human Growth Hormone; Humans; Interviews as Topic; Male; Middle Aged; Octreotide; Peptides, Cyclic; Personal Satisfaction; Somatostatin; Surveys and Questionnaires | 2019 |
An observational study of pregnancy and post-partum outcomes in women with prolactinoma treated with dopamine agonists.
Topics: Abortion, Spontaneous; Adenoma; Adolescent; Adult; Bromocriptine; Cabergoline; Cohort Studies; Dopamine Agonists; Female; Humans; Infertility; Lactation; Pituitary Neoplasms; Postpartum Period; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Prolactinoma; Retrospective Studies; Young Adult | 2020 |
Long-term safety and treatment outcomes of pegvisomant in Japanese patients with acromegaly: results from the post-marketing surveillance.
Topics: Acromegaly; Adenoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Bromocriptine; Cabergoline; Chemical and Drug Induced Liver Injury; Child; Disease Progression; Dopamine Agonists; Drug Therapy, Combination; Female; Growth Hormone-Secreting Pituitary Adenoma; Human Growth Hormone; Humans; Hypoglycemia; Insulin-Like Growth Factor I; Japan; Male; Middle Aged; Neurosurgical Procedures; Octreotide; Peptides, Cyclic; Product Surveillance, Postmarketing; Radiotherapy; Receptors, Somatotropin; Somatostatin; Tumor Burden; Young Adult | 2020 |
Prevalence, incidence, comorbidities, and treatment patterns among Japanese patients with acromegaly: a descriptive study using a nationwide claims database.
Topics: Acromegaly; Adenoma; Adult; Aged; Antineoplastic Agents, Hormonal; Bromocriptine; Cabergoline; Comorbidity; Dopamine Agonists; Female; Growth Hormone-Secreting Pituitary Adenoma; Human Growth Hormone; Humans; Hyperlipidemias; Hypertension; Incidence; Japan; Male; Middle Aged; Neurosurgical Procedures; Octreotide; Peptides, Cyclic; Prevalence; Radiosurgery; Radiotherapy, Intensity-Modulated; Retrospective Studies; Somatostatin; Young Adult | 2020 |
Therapeutic activity of sarpogrelate and dopamine D
Topics: Animals; Blood Glucose; Bromocriptine; Cabergoline; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Dopamine Agonists; Drug Therapy, Combination; Isoenzymes; Kidney; L-Lactate Dehydrogenase; Male; Myocardial Infarction; Myocardium; Rats, Wistar; Serotonin 5-HT2 Receptor Antagonists; Succinates; Troponin I; Tumor Necrosis Factor-alpha | 2021 |
ACT001 reverses resistance of prolactinomas via AMPK-mediated EGR1 and mTOR pathways.
Topics: AMP-Activated Protein Kinases; Antineoplastic Combined Chemotherapy Protocols; Bromocriptine; Cabergoline; Drug Resistance, Neoplasm; Drug Synergism; Early Growth Response Protein 1; Furans; Humans; Pituitary Neoplasms; Prolactinoma; TOR Serine-Threonine Kinases | 2021 |
Dopamine agonist for the rapid improvement of visual field defects in giant and macro-prolactinomas.
Topics: Bromocriptine; Cabergoline; Dopamine Agonists; Female; Humans; Male; Pituitary Neoplasms; Prolactin; Prolactinoma; Retrospective Studies; Vision Disorders; Visual Fields | 2022 |
The Inhibitory Effect of Selected D
Topics: Angiogenesis Inhibitors; Animals; Bevacizumab; Bromocriptine; Cabergoline; Dopamine Agonists; Hypoxia; Larva; Neovascularization, Pathologic; Pergolide; Vascular Endothelial Growth Factor A; Zebrafish | 2022 |
Cabergoline treatment promotes myocardial recovery in peripartum cardiomyopathy.
Topics: Animals; Bromocriptine; Cabergoline; Cardiomyopathies; Dopamine Agonists; Female; Heart Failure; Mice; MicroRNAs; Myocytes, Cardiac; Peripartum Period; Pregnancy; Prolactin; Ventricular Dysfunction, Left | 2023 |
Long-term low-dose cabergoline usage: Another association with cardiac valvulopathy.
Topics: Bromocriptine; Cabergoline; Ergolines; Heart Valve Diseases; Humans; Middle Aged; Pituitary Neoplasms | 2023 |
Italian Guidelines for the Management of Prolactinomas.
Topics: Adult; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Humans; Pituitary Neoplasms; Prolactin; Prolactinoma | 2023 |